The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Wednesday:** Biogen Idec is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug.
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. Shares of BIIB traded higher by 2.3% or $3.62/share to $160.98. In the past year, the shares have traded as low as $114.53 and as high as $158.39. On average, 1299780 shares of BIIB exchange hands on a given day and today's volume is recorded at 2822904.
Source
